Expression of survivin (BIRC5), epidermal growth factor (ErbB-2/HER2-Neu), vascular endothelial growth factor (VEGF) and anti-oncogene TP53 in toxoplasmosis during the development of experimental glioma

The article describes the results obtained in the study of the expression of survivin (BIRC5), epidermal growth factor (ErbB-2/HER2-Neu), vascular endothelial growth factor (VEGF) and TP53 anti-oncogene in toxoplasmosis during the development of experimental glioma.The studies were carried out on female Wistar rats. The first series was «control with tumor» taking biopsies of the tumor and liver on the 14th, 21st, 28th, 35th, 42nd and 49th days of tumor development.The second series was aimed at elucidating the question of the effect of T. gondii on changes in the expression level of protooncogenes survivin (BIRC5), epidermal growth factor (ErbB-2/HER2-Neu), vascular endothelial growth factor (VEGF) and TP53 anti-oncogene in comparison with genes referenced β-actin (ACTB) and GAPDH during the reproduction of an experimental carcinogenic process depending on the period of development of Toxoplasma. Rats were infected orally at a dose of 50 tachyzoites per 1 g of animal body weight (10,000 tachyzoites per female) on the 7th day after in situ injection of C6 glioma tumor cells. The animals were removed from the experiment according to the schedule: on the 14th day of glioma development (7th day after invasion), 21st day of tumor development (14th day after invasion), 28th day of tumor development (21st day after invasion), 35th day of glioma development (28th day after invasion), 42nd day of tumor development (35th day after invasion) and 49th day of development of glioma (42nd day after invasion) and sampling material (tumor, liver).It was revealed that invasion at a dose of 50 Toxoplasma tachyzoites per 1 g of body weight (10,000 tachyzoites per female) of an animal during tumor development leads to an increase in the expression of survivin (BIRC5), VEGF, ErbB-2/HER2-Neu in tumor and liver biopsies collected on the 7th, 14th, 21st, 28th, 35th, 42nd days of the development of the parasite in comparison with uninfected animals with a tumor.Infection of female rats with glioma at a dose of 50 Toxoplasma tachyzoites per 1 g of body weight (10 000 tachyzoites per female) leads to a decrease in the expression of the TP53 anti-oncoge

expression, survivin (BIRC5), epidermal growth factor (ErbB-2/HER2-Neu), vascular endothelial growth factor (VEGF), anti-oncogene TP53, toxoplasma, rats

1. Генные механизмы возникновения раковых опухолей / В.М. Семенов [и др.] // Здравоохранение HELTHCARE. - 2017. - №7. - С. 38-47.

2. Li, F. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? / F. Li, I. Aljahdali, X. Ling // J Exp Clin Cancer Res. - 2019. Vol. 22, № 38(1). - Р. 368.

3. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis / CS. Melincovici [et al.] // Rom J Morphol Embryol. - 2018. - Vol. 59 (2). - Р. 455-467.

4. Cancer vaccines co-targeting HER2/Neu and IGF1R / De Giovanni C [et al.] //, Cancers (Basel). - 2019. - Vol. 11 (4). - Р. 517.

5. Gli proteins: regulation in development and cancer / P. Niewiadomski [et al.] // Cells. - 2019. - Vol. 8(2). - Р. 147.

6. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas / LA. Donehower [et al.] // Cell Rep. - 2019. Vol. 28 (5). - Р. 1370 -1384. e5

7. Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk / M.E. Langston [et al.] // Prostate. - 2019. - Vol. 79, № 14. - Р. 1622-1628.

8. High association of Cryptosporidium spp. infection with colon adenocarcinoma in Lebanese patients / M. Osman [et al.] // PLoS One. - 2017. Vol. 12, № 12. - e0189422.

9. Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia / A. G. Abdou [et al.] // Int. J. Infect. Dis. - 2013. Vol. 17, № 8. - P. e593-e600.

10. Bouzid, M. Risk factors for Cryptosporidium infection in low and middle income countries: a systematic review and meta-analysis // M. Bouzid, E. Kintz, P.R. Hunter // PLoS Negl. Trop. Dis. - 2018. Vol. 12, № 6. - e0006553.

11. Пашинская, Е.С. Паразитирование токсоплазм и его некоторые медико-биологические аспекты (обзор литературы, часть 1) / Е.С. Пашинская, В.В. Побяржин, В.М. Семенов // Медико-биологические проблемы жизнедеятельности. - 2018. - № 1 (19). - С. 14-24.

12. Toxoplasma gondii in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level / Mona Ibrahim Ali [et al.] //j. Parasit. Dis. - 2019 - Vol. 43, № 3. - Р. 464-471.

13. Toxoplasma modulates signature pathways of human epilepsy / H. M. Ngô [et al.] // Sci. Rep. - 2017. - Vol. 7, № 1. - Р. 11496.

14. High Toxoplasma gondii Seropositivity among Brain Tumor Patients in Korea / Bong-Kwang Jung [et al.] // Korean J. Parasitol. - 2016. - Vol. 54, № 2. - Р. 201-204.

15. Пашинская, Е.С. Способ воспроизведения экспериментальной крысиной глиомы С6 in situ / Е.С. Пашинская, В.В. Побяржин // Медико-биологические проблемы жизнедеятельности. - 2019. - № 2 (22). - С. 50-55.